Table SIII. *Summary of clinical and therapeutic data of pemphigus patients from included studies and divided into high dose protocol, low dose protocol, and plus IA protocol*

Study	Mean age (years)	Disease duration (years)	TDC (week)[a]	TCRon (months)[a]	CR (%)[b]	Remission duration of CR (months)	Relapse, *n* (%)	Major adverse event (%)	Mean follow-up time (months)
High-dose group									
Lymphoma protocol (total 2,595 mg by standardized body surface area of 1.73 m^2)									
Arinet al. (4), 2005	47.4 ± 19.4	6.8 ± 4.6	N/A	5.3	3/5 (60)	20.7	2/5 (40)	0	19.6
Goh et al. (7), 2007	54 ± 6.7	3.4 ± 2.9	N/A	5.6	3/5 (60)	10.7	0	2/5 (40), opportunistic infection	16.8
Marzano et al. (8), 2007	43.6 ± 7.6	5.2 ± 1.5	6.4	3	4/5(80)	8.9	1/5 (20)	0	16.4
Antonucci et al. (5), 2007	30.6 ± 2.7	4.8 ± 1.6	4.4	3	5/5 (100)	9	1/5 (20)	0	12
Cianchini et al. (6), 2007	42.3 ± 10.2	3.9 ± 3.7	4	4	9/12 (75)	6.9	0	0	10.5
Schmidt et al. (9), 2009	52.4	N/A	N/A	6	2/3 (66.7)	9	1/3 (33.3)	0	15
Kim et al. (11), 2011	N/A	N/A	2.5	3.8	9/16 (56.3)	N/A	5/16 (31.3)	0	36
Kasperkiewicz et al. (10), 2011	47.5	3.5	N/A	3	1/2 (50)	56	1/2 (50)	0	25.4
Reguiai et al. (13), 2012	40 ± 18.9	6.9 ± 6.6	N/A	6	13/13 (100)	23.9	7/13 (53.8)	0	45.6
Lunardon et al. (12), 2012	44.9 ± 11.3	7.58 ± 6.3	N/A	N/A	4/15 (26.7)	N/A	2/15 (13.3)	0	40.8
Colliou et al. (35), 2013	53.7 ± 15.6	N/A	N/A	8.4	20/21 (95.3)	31.8	17/21(81)	2/21 (9.5); pyelonephritis and septicaemia	74
Baum et al. (15), 2013	50.9 ± 11.6	7.4 ± 6.4	N/A	5.3	13/18 (72.2)	5.3	4/18 (22.2)	0	16
Balighi et al. (14), 2013	40.5	2.9	2.4	9.1	40/40 (100)	N/A	21/41 (52.5)	4/40 (10%); lung abscess, cavernous sinus thrombosis, sepsis, SJS	12
Cho et al. (31), 2013	54.5 ± 17.1	4.1 ± 3.9	6.2 ± 3.2	4.3 ± 1.2	4/8 (50)	14.5	5/8 (62.5)	0	24.9
Gregoriou et al. (17), 2014	49 ± 16.6	5.1 ± 4.2	5	N/A	18/18 (100)	N/A	7/18 (38.9%)	0	9–48
Total lymphoma data (n=186)	46 (*n*=170)	5.0 (*n*=146)	3.6 (*n*=104)	6.6 (*n*=126)	148/186 (79.6)	18.2 (*n*=75)	74/186 (39.8)	8/186 (4.3)	29.1 (*n*=168)
RA protocol (total 2,000 mg)									
Kasperkiewicz et al. (10), 2011	42.3	1.56	N/A	3	4/4(100)	14	3/4(75)	0	20.5
Cianchini et al. (6), 2012	27–75	4.2	N/A	3	36/42 (86)	N/A	20/42 (47.6)	0	26.5
Lunardon et al. (12), 2012	49.2	3.3 ± 3.1	N/A	N/A	9/16 (56.3)	N/A	2/16 (12.5)	2/31 (12.5); phlegmon and osteomyelitis	23.4
Leshem et al. 19), 2013	52 (18–83)	2.1 (0–13.6)	N/A	4 (1–36)	28/45 (62.2)	N/A	5/45 (11.1)	0	18
Kanwar et al. (24), 2013	36.5 ± 12.5	1.6 ± 1.9	8	N/A	6/9 (66.7)	N/A	N/A	2/9 (22.2) sepsis	8
Heelan et al. 20), 2014	47 (17–77)	2 (0–21.3)	N/A	N/A	74/92 (80)	N/A	56/92 (61)	0	24
Kanwar et al. (21), 2014	33.2	2.1	7.1 ± 3.5	5.9	10/11 (90.9)	5.1	4/11 (36.4)	0	12
Total RA data (*n*=219)	42.9 (*n*=40)	3.3 (*n*=82)	7.2 (*n*=19)	3.8 (*n*=50)	167/219 (76.3)	7.6 (*n*=14)	90/219 (42.9)	4/219 (1.8)	21.8 (*n*=219)
Others (total near or ≥2,000 mg)[c]									
Kim et al. (22), 2011	47.7 ± 14.3	1.7	4 (1–10)	5.0 (2.1–13.2)	11/15 (73)	N/A	0	0	18
Kasperkiewicz et al. (27), 2012	52	N/A	N/A	N/A	4/22 (18.2)	N/A	N/A	N/A	11
Cho et al. (31), 2013	54.1 ± 16.0	0	2.2	3.85	9/9 (100)	6.6	8/9(88.9)	0	20.5
Cho et al. (16), 2013	57	3.1	5.5	3.8	2/2 (100)	24.4	2/2 (100)	0	28.3
Total high-dose data (*n*=453)	46.5 (*n*=258)	4.1 (*n*=254)	3.9 (*n*=149)	5.7 (*n*=185)	354/453 (78.1)	15.8 (*n*=100)	172/422 (40.8)	12/431 (2.8)	23.9 (*n*=435)

Table SIII. *Contd.*

Low-dose group (total <1,500 mg)									
Kasperkiewicz et al. (10), 2011	50	0.33	N/A	3	1/1 (100)	9	0	0	12
Kim et al. (22), 2011	48.4 ± 10.1	3.5 ± 2.1	3 (1–11)	14.4 (3.1–29.2)	5/12 (42)	N/A	8/12 (67)	0	11.5
Horváth et al. (23), 2012	55.1 ± 15.1	6.1 ± 3.2	9.8	11.5	8/15 (53.3)	7.1	6/15 (40)	1/15 (6.7) sepsis	21.3
Cho et al. (16), 2013	51.5 ± 13.2	4.4 ± 3.0	3.9	3.5	9/13 (69.2)	15.3	3/13 (23.1)	0	18
Kanwar et al. (21), 2014	33.5	1.3	7.4 ± 4.5	4.2	11/11 (100)	5.5	7/11 (63.6)	0	12
Total low-dose data (n=52)	48.0 (n=52)	4.1 (52)	6 (n=51)	6.1 (n=29)	34/52 (65.4)	9.1 (n=29)	24/52 (46.2)	1/52 (1.9)	16.6 (n=52)
Rituximab (high dose) plus immunoadsorption protocol									
Shimanovich et al. (25), 2008	56.9 ± 16.9	2.9 ± 2.3	–2[d]	3.75	3/7 (42.9)	16.3	3/7(42.9)	3/7 (42.9); PCP, staphylococcal bacteremia and PE	23.3
Schmidt et al. (9), 2009	52.4	N/A	N/A	5	3/8 (37.5)	10	4/8 (50)	0	15
Kasperkiewicz et al. (10), 2011	53.3	2.7	N/A	3.3	3/3 (100)	9.3	3/3 (100)	0	29
Kasperkiewicz et al. (28), 2012	54.3 ± 12.7	3.0	–1.3[d]	8.2	22/23 (95.7)	17.7	6/23 (26)	2/23 (9); staphylococcal bacteremia and extensive herpes simplex infection	29
Behzad et al. (26), 2012	52.1 ± 9.8	5.4 ± 2.6	N/A	3.3	8/10 (80)	7.3	1/10 (10)	0	10.8
Kasperkiewicz et al. (27), 2012	52	N/A	N/A	N/A	4/14 (29)	N/A	N/A	N/A	11
Kolesnik et al. (29), 2014	59.5 ± 13.3	4.0 ± 6.7	–1[d]	4.7	7/8 (87.5)	20.6	1/8 (12.5)	0	20.5
R+IA total data (n=73)	54.1 (n=73)	3.6 (n=51)	N/A	6.1 (n=46)	50/73 (68.5)	15.2 (n=46)	18/59 (30.5)	5/73 (8.5)	21.1 (n=73)
Overall total data (n=578)	48.2 (n=383)	4.1 (n=357)	4.4 (n=200)	5.8 (n=262)	438/578 (75.8)	14.5 (n=175)	214/533 (40.2)	18/542 (3.3)	22.9 (n=560)

[a]Started from the end of rituximab (RTX) treatment. [b]Complete remission according to the definition of the original study (Table SI). [c]The group classified as "Others" included patients receiving high-dose regimens other than RA or lymphoma protocols and those using high-dose RTX without detailed information in Kasperkiewicz et al. (17), 2012. [d]Onset immediately after starting IA and before completion of the RTX regimen.
Data expressed as mean ± standard deviation (if available) or percentage.
Comparisons by analysis of variance (ANOVA) or χ^2 test.
CR: complete remission; TDC: time to disease control; TCRon: time to complete remission on therapy; IA: immunoadsorption; RA: rheumatoid arthritis; SJS: Stevens–Johnson syndrome; PCP: pneumocytosis carinii pneumonia; PE: pulmonary embolism; N/A: not applicable.